Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105586 · ClinicalTrials.gov registry record · Phase 4
Drug Therapy for Generalized Anxiety Disorder Among the Elderly
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 177
- Enrollment target
NCT00105586 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 177 participants.
The verdict
NCT00105586, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 177 participants
- Enrollment target
Study Summary
This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105586
The ClinicalTrials.gov registry entry for NCT00105586 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00105586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105586 about?
NCT00105586 is a clinical study titled "Drug Therapy for Generalized Anxiety Disorder Among the Elderly". This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.
What is the current status of trial NCT00105586?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 177 participants. The study started on 2004-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00105586?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00105586?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.